Bone Graft Substitute Market - Forecasts from 2023 to 2028

The bone graft substitute market is expected to grow at a CAGR of 6.43% during the forecast period.

Bone graft substitutes are used to prevent disease transmission and donor-site complications and reduce operative time. The rising bone diseases and orthopedic surgeries among the population are major growth factors in the bone graft substitute market. Moreover, the increasing demand from the dental sector due to the rising number of implant procedures is also expected to propel the bone graft substitute market in the coming years. Additionally, the technological advancements leading to enhanced synthetic bone graft accessibility coupled with approval of products by the government are further contemplated to boost the bone graft substitute market.

Growing Prevalence of Bone Diseases

There is various health condition related to bone density and minerals such as osteoporosis, osteopenia, Paget’s disease, osteogenesis imperfecta, and osteoarthritis, among others creating a musculoskeletal problem. The growing cases of these bone-related diseases are pushing the demand for bone graft substitutes to improve or replace autogenous bone grafts. According to WHO, around 1.71 people had musculoskeletal problems worldwide in 2022 and it is the leading cause of disability. Moreover, musculoskeletal problems are the biggest contributor to years lived with disability (YLD) accounting for 17% of total YLDs globally. Bone disease causes serious health problems affecting physical, mental, and emotional health if not treated on time. The adverse effect along with the rising cases is anticipated to propel the bone graft substitute market.

Rising Orthopedic Surgeries

The rising number of bone diseases and osteoporosis is leading to more orthopedic surgeries and thereby propelling the bone graft substitute market. For instance, Gelenk Klinik Hospital of Germany treats more than 24,000 orthopaedic patients per year with more than 2400 cases involving surgical procedures. Around 2 million joint replacement surgeries happen in the US every year as per the estimates of Business Standard.

Increasing Demand for Dental Implants

The demand for bone graft substitutes in dentistry is rising owing to the growing number of dental implant procedures and patients’ preference for minimally invasive procedures. There are several bone graft substitutes available in the market including allograft, autograft, xenograft, alloplastic, and sinus lift. According to the American Academy for Implant Dentistry, approximately 15 million Americans replace missing teeth with bridges and crowns each year, which increases the need for dental implants thereby propelling the bone graft substitutes market. Moreover, in almost 40% of all implant cases, there is insufficient bone to achieve good implant integration, necessitating the use of bone graft replacements as per the Implant Dentistry Official Journal.

Aging Population

Ageing populations are more prone to low bone density leading to numerous bone diseases and surgery. The growing number of ageing people worldwide indicates the need for bone graft substitutes in the coming years. For instance, the number of people aged 60 or above will increase to 1.4 billion by 2030 from 1 billion in 2020 and it is projected to reach 2.1 billion by 2050 as per the WHO estimates. In old age, bones become brittle and there is a higher chance of breaking leading to more cases of osteoporosis in this age group. According to the Bone and Joint Burden Organization, nearly 3 out of 4 people aged 65 or above suffer from musculoskeletal disease indicating the bone graft substitute market expansion.

Opportunities in the Market

The rising orthopedic and bone diseases coupled with the demand for minimally invasive surgical procedures are propelling the bone graft substitute market thereby providing a phenomenal opportunity for new entrants. Moreover, the favorable government regulations and approvals of bone graft substitutes further extend an expansion opportunity. In 2021, there were 24 types of bone graft substitutes approved by the FDA including PMMA Bone Cement, Bioactive Glass, Calcium Sulfate, Calcium Phosphate Cement, and Biphasic Calcium Phosphate among others. Furthermore, the technological advancements to enhance patient experience and comfort in diversified implantation for dental, spinal, and orthopedic are also expected to boost the bone graft substitute market size leading to increased opportunity.

North America is expected to grow considerably during the forecast period

North American region is expected to hold a significant share of the bone graft substitute market during the forecasted period. Various factors attributed to such a significant share are a huge number of osteoporosis cases, government approvals, and technological advancements in the region. For instance, approximately 54 million Americans have osteoporosis currently as per the Bone Health and Osteoporosis Foundation. Moreover, osteoporosis causes around two million broken bones every year in America and one in two women are expected to have a bone fracture by the age of 50 due to osteoporosis. Further, the presence of some of the market leaders such as Arthrex, Johnson & Johnson, and Stryker Corporation in the region is also expected to boost the bone graft substitute market through increasing accessibility and product advancements.

Key Developments

• In May 2023, Bio-Reign 3D bone graft substitute was launched by the Royal Biologics which is made with a natural hyper-crosslinked carbohydrate polymer. It enables bone formation with its degradation profile, and it becomes radiopaque as the bone heals.
• In March 2022, the full commercial launch of the Osteo-P® synthetic bone graft substitute was announced by Molecular Matrix. The hyper-crosslinked carbohydrate polymer (HCCP) technology was used to create it to repair and regenerate bone.
• In June 2020, a new bone graft substitute SIGNAFUSE was launched by Bioventus in a new strip format. The mineral structure of the bone graft was made with 60% hydroxyapatite and 40% beta-tricalcium phosphate.

Company Products

• Arthrex, a US-based company focuses on orthopaedics to help surgeons better treat their patients. The company offers OSferion which is an osteoconductive bone graft substitute made from 100% beta-tricalcium phosphate.
• Johnson & Johnson, it is a multi-specialty healthcare company offering services since the 1940s. In May 2023, the company got clearance from the FDA to use its INHANCE™ shoulder system in reverse shoulder replacement surgeries. The company offers synthetic chronOS® Bone Graft Substitute (CMF) made with beta-tricalcium phosphate and it is available as granules and preformed shapes.
• Medtronic Plc, they are one of the leading medical technology companies which provide advanced surgical technology solutions. The bone grafting substitute offered by the company is Grafton™ DBF inject, Infuse™ Bone Graft, Magnifuse™ Bone Graft, and Mastergraft™ Family for minimally invasive and open procedures.

Segmentation:

By Type

• Allografts
• Bone grafts Substitutes
• Cell-based Matrices

By Application

• Spinal Fusion
• Trauma
• Joint Reconstruction
• Dental Bone Grafting
• Craniomaxillofacial

By End-User

• Hospitals
• Specialty Clinics
• Others

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others